Archive: Company News
Company News: Standard reference ‘Infections of the musculoskeletal system’ is now available for free as an e-book
– As the publisher, Heraeus Medical is making the 2nd edition of the reference available for download
Heraeus Medical has financed and published the current 2nd edition of the standard reference ‘Infections of the musculoskeletal system’ and is making it available for free in the form of an e-book. Read more…
Company News: Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC
— First data of phase I/II trial in HPV16-positive patients with late-stage cervical cancer
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, today announced that results of a company-sponsored clinical Phase I/II trial in late-stage cervical cancer (ISA101-CervISA) will be presented at the inaugural ASCO-SITC congress on immuno-oncology (February 23-25, 2017, Orlando, FL, USA).
Company News: Multiplexed Analysis of ALK, ROS1, and RET Rearrangements in Lung Cancer Enabled by the MassARRAY® System
Agena Bioscience today announced a comparative study published in Scientific Reports highlighting the use of its mass spec-based platform for transcriptome analysis of ALK, ROS1, and RET gene fusions in lung cancer.
Company News: Anergis Completes Patient Recruitment in Large-Scale ATIBAR Trial with Ultra-Fast Allergy Immunotherapy AllerT
— 421 patients randomized at 38 European trial centers
— Top-line results expected in Q3, 2017
Anergis, a company developing proprietary ultra-fast allergy immunotherapy, announced today that it has completed patient recruitment in the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.